New changes in pregnancy and lactation labelling: Review of dermatologic drugs
- PMID: 31700976
- PMCID: PMC6831768
- DOI: 10.1016/j.ijwd.2019.05.002
New changes in pregnancy and lactation labelling: Review of dermatologic drugs
Abstract
Background: The U.S. Food and Drug Administration has published new pregnancy and lactation labelling rules that set standards on the presentation of information with regard to drug usage during pregnancy and breastfeeding, as well as the effects on fertility. These guidelines became effective June 30, 2015, and classified the risks of using prescription drugs during pregnancy in three detailed subsections: Pregnancy, Lactation, and Females and Males of Reproductive Potential. These sections describe the risks within a real-world context of caring for these patients.
Objective: In this study, we reclassified and categorized drugs and treatments commonly used in dermatology according to these new guidelines.
Methods: We performed a search of the medical literature about the use of relevant prescription drugs during pregnancy and breastfeeding and their effect on fertility. The search included prospective and retrospective studies, review articles from PubMed-indexed journals (from inception to November 2018), U.S. Food and Drug Administration records, pregnancy exposure registries, relevant information and studies provided in drug labeling by companies, and updated pharmacologic texts and guidelines up to 2018.
Results: Topical immunomodulators, systemic immunomodulators (including biologics), systemic antipruritic agents, antimicrobials, as well as acne, hair, and cosmetic agents were included. We have made best attempts to review and consolidate existing and new data and include them in our guide.
Conclusion: This new narrative format facilitates prescribing by considering a variety of factors. One previously overlooked aspect was the impact on the reproductive potential of both male and female patients. Rather than depending on overly simplistic letter risk categories, dermatologists will now need to make prescribing decisions based on each patient and the information provided, which will allow for better decision making and patient care.
© 2019 Published by Elsevier Inc. on behalf of Women's Dermatologic Society.
Similar articles
-
Healthcare providers' use of a concise summary to prescribe for lactating patients.Res Social Adm Pharm. 2024 May;20(5):531-538. doi: 10.1016/j.sapharm.2024.02.004. Epub 2024 Feb 19. Res Social Adm Pharm. 2024. PMID: 38413289
-
Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule.Fed Regist. 2014 Dec 4;79(233):72063-103. Fed Regist. 2014. PMID: 25509060
-
Clinicians' Perspective of the New Pregnancy and Lactation Labeling Rule (PLLR): Results from an AAAAI/FDA Survey.J Allergy Clin Immunol Pract. 2020 Jun;8(6):1947-1952. doi: 10.1016/j.jaip.2020.01.056. Epub 2020 Feb 19. J Allergy Clin Immunol Pract. 2020. PMID: 32084595
-
Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy.J Am Acad Dermatol. 2014 Mar;70(3):401.e1-14; quiz 415. doi: 10.1016/j.jaad.2013.09.010. J Am Acad Dermatol. 2014. PMID: 24528911 Review.
-
Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation.J Am Acad Dermatol. 2014 Mar;70(3):417.e1-10; quiz 427. doi: 10.1016/j.jaad.2013.09.009. J Am Acad Dermatol. 2014. PMID: 24528912 Review.
Cited by
-
Clinical considerations in the management of hidradenitis suppurativa in women.Int J Womens Dermatol. 2021 Oct 29;7(5Part B):664-671. doi: 10.1016/j.ijwd.2021.10.012. eCollection 2021 Dec. Int J Womens Dermatol. 2021. PMID: 35028361 Free PMC article. Review.
-
Atopic dermatitis in women: special considerations in the childbearing years.Int J Womens Dermatol. 2024 Jun 10;10(2):e151. doi: 10.1097/JW9.0000000000000151. eCollection 2024 Jun. Int J Womens Dermatol. 2024. PMID: 38860232 Free PMC article.
-
A Guide to the Management of Hidradenitis Suppurativa in Pregnancy and Lactation.Am J Clin Dermatol. 2025 May;26(3):345-360. doi: 10.1007/s40257-025-00935-x. Epub 2025 Mar 25. Am J Clin Dermatol. 2025. PMID: 40131719 Free PMC article. Review.
References
-
- Ahmed A.R., Gurcan H.M. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2011;25:1073–1079. - PubMed
-
- Autret E., Berjot M., Jonville-béra A.P., Aubry M.C., Moraine C. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet. 1997;350(9074):339. - PubMed
-
- Baker H.W., Straffon W.G., McGowan M.P., Burger H.G., De Kretser D.M., Hudson B. A controlled trial of the use of erythromycin for men with asthenospermia. Int J Androl. 1984;7(5):383–388. - PubMed
-
- Both T., Van Laar J.A., Bonte-Mineur F., Van Hagen P.M., Van Daele P.L. Colchicine has no negative effect on fertility and pregnancy. Ned Tijdschr Geneeskd. 2012;156(12):A4196. - PubMed
LinkOut - more resources
Full Text Sources